Concomitant weekly cisplatin and radiotherapy for head and neck cancer

Japanese Journal of Clinical Oncology

Volumn 41, Issue 8, 2011, Pages 980-986

  Homma, Akihiro ^a   Inamura, Naoya ^a   Oridate, Nobuhiko ^a   Suzuki, Seigo ^a   Hatakeyama, Hiromitsu ^a   Mizumachi, Takatsugu ^a   Kano, Satoshi ^a   Sakashita, Tomohiro ^a   Onimaru, Rikiya ^a   Yasuda, Koichi ^a   Shirato, Hiroki ^a   Fukuda, Satoshi ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemoradiotherapy; Chemotherapy; Cisplatin; Radiotherapy

Indexed keywords

CISPLATIN;

ADENOCARCINOMA; ADULT; AGED; ANEMIA; APPETITE DISORDER; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHEMORADIOTHERAPY; DERMATITIS; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEAD AND NECK CANCER; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; HYPERNATREMIA; HYPONATREMIA; HYPOPHARYNX CANCER; JAW OSTEONECROSIS; KIDNEY DISEASE; LARYNX CANCER; LEUKOPENIA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUTROPENIA; OROPHARYNX CANCER; OVERALL SURVIVAL; PATIENT COMPLIANCE; PATIENT MONITORING; PROGRESSION FREE SURVIVAL; RADIATION DOSE; SEPSIS; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; FEMALE; HUMANS; HYPOPHARYNGEAL NEOPLASMS; KAPLAN-MEIER ESTIMATE; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; OROPHARYNGEAL NEOPLASMS; OTORHINOLARYNGOLOGIC NEOPLASMS; RADIOTHERAPY, HIGH-ENERGY; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79961049647     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyr086     Document Type: Article

References (23)

1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Head and Neck Cancers, 2010, version 2. http://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf696.
2. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349:2091-8.
3. Adelstein DJ, Li Y, Adams GL, Wagner H, Jr, Kish JA, Ensley JF, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21:92-8.
4. Machtay M, Moughan J, Trotti A, Garden AS, Weber RS, Cooper JS, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 2008;26:3582-9.
5. Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998;16:1310-7.
6. Jeremic B, Shibamoto Y, Milicic B, Nikolic N, Dagovic A, Aleksandrovic J, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol 2000;18:1458-64.
7. Wee J, Tan EH, Tai BC, Wong HB, Leong SS, Tan T, et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol 2005;23:6730-8.
8. Huguenin P, Beer KT, Allal A, Rufibach K, Friedli C, Davis JB, et al. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol 2004;22:4665-73.
9. Nishimura G, Tsukuda M, Horiuchi C, Satake K, Yoshida T, Taguchi T, et al. Decrease of creatinine clearance rate with aging in patients with head and neck cancer in Japan. Int J Clin Oncol 2007;12:120-4.
10. Isobe K, Kawakami H, Uno T, Yasuda S, Aruga T, Ueno N, et al. Concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: is intergroup study 0099 feasible in Japanese patients?. Jpn J Clin Oncol 2003;33:497-500.
11. Chan AT, Leung SF, Ngan RK, Teo PM, Lau WH, Kwan WH, et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 2005;97:536-9.
12. Bahl M, Siu LL, Pond GR, Kim J, Tannock IF, Bayley A, et al. Tolerability of the Intergroup 0099 (INT 0099) regimen in locally advanced nasopharyngeal cancer with a focus on patients' nutritional status. Int J Radiat Oncol Biol Phys 2004;60:1127-36.
13. de Castro G, Jr, Snitcovsky IM, Gebrim EM, Leitao GM, Nadalin W, Ferraz AR, et al. High-dose cisplatin concurrent to conventionally delivered radiotherapy is associated with unacceptable toxicity in unresectable, non-metastatic stage IV head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol 2007;264:1475-82.
14. Ho KF, Swindell R, Brammer CV. Dose intensity comparison between weekly and 3-weekly Cisplatin delivered concurrently with radical radiotherapy for head and neck cancer: a retrospective comparison from New Cross Hospital, Wolverhampton, UK. Acta Oncol 2008;47:1513-8.
15. Quon H, Leong T, Haselow R, Leipzig B, Cooper J, Forastiere A. Phase III study of radiation therapy with or without cis-platinum in patients with unresectable squamous or undifferentiated carcinoma of the head and neck: an intergroup trial of the Eastern Cooperative Oncology Group (E2382). Int J Radiat Oncol Biol Phys (in press).
16. Homma A, Shirato H, Furuta Y, Nishioka T, Oridate N, Tsuchiya K, et al. Randomized phase II trial of concomitant chemoradiotherapy using weekly carboplatin or daily low-dose cisplatin for squamous cell carcinoma of the head and neck. Cancer J 2004;10:326-32.
17. Marcu L, van Doorn T, Olver I. Cisplatin and radiotherapy in the treatment of locally advanced head and neck cancer-a review of their cooperation. Acta Oncol 2003;42:315-25.
18. Browman GP, Hodson DI, Mackenzie RJ, Bestic N, Zuraw L. Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: a systematic review of the published literature with subgroup analysis. Head Neck 2001;23:579-89.
19. Zenda S, Onozawa Y, Tahara M, Kawashima M, Shikama N, Sasaki S, et al. Feasibility study of single agent cisplatin and concurrent radiotherapy in Japanese patients with squamous cell carcinoma of the head and neck: preliminary results. Jpn J Clin Oncol 2007;37:725-9.
20. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11:21-8.
21. Pfister DG, Su YB, Kraus DH, Wolden SL, Lis E, Aliff TB, et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a Pilot phase ii study of a new combined-modality paradigm. J Clin Oncol 2006;24:1072-8.
22. Langer CJ, Lee JW, Patel UA, Shin DM, Argiris AE, Quon H, et al. Preliminary analysis of ECOG 3303: Concurrent radiation (RT), cisplatin (DDP) and cetuximab (C) in unresectable, locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN). Proc Am Soc Clin Oncol 2008;26(Suppl): abstr 6006.
23. Lefebvre J, Pointreau Y, Rolland F, Alfonsi M, Baudoux A, Sire C, et al. Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): preliminary results of the randomised phase II TREMPLIN study. Proc Am Soc Clin Oncol 2009;27(Suppl):303s.